Dose-dumping resistant controlled release dosage form
View Patent ↗The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
1. A dosage form comprising an extended release composition comprising methylphenidate (MPH) or salt thereof, wherein the extended release composition exhibits a less than 1.5-fold ethanol-related increase in the total amount of MPH or salt thereof released from the extended release composition during the first 120 minutes when comparing the MPH or salt thereof release rates in aqueous 0.1 N HCl at 37±1° C. and in 40% ethanol in aqueous 0.1 N HCl at 37±1° C., wherein, for the extended release composition, about 25% to about 35% wt of MPH or salt thereof is released by about 2 hours, about 45% to about 60% wt of MPH or salt thereof is released by about 4 hours, about 65% to about 85% of MPH or salt thereof is released by about 6 hours, about 85% to about 100% wt of MPH or salt thereof is released by about 8 hours and no less than 85% of MPH or salt thereof is released by about 10 hours after placement in aqueous 0.1 N HCl at 37±1° C.
2. The dosage form of claim 1 , wherein the extended release composition exhibits a less than 2-fold ethanol-related increase in the average rate of MPH or salt thereof released from the extended release composition during the time period of 15 minutes to 120 minutes when comparing the release rates in aqueous 0.1 N HCl at 37±1° C. and in 40% ethanol in aqueous 0.1 N HCl at 37±1° C.
3. The dosage form of claim 1 further comprising a MPH-containing or MPH salt-containing rapid release or immediate release composition.
4. The dosage form of claim 3 , wherein the MPH or salt thereof is divided between the rapid release or immediate release composition and the extended release composition according to the following proportions: a) 1-40% wt in the rapid release or immediate release composition and 99-60% wt in the extended release composition; b) 10-40% wt in the rapid release or immediate release composition and 90-60% wt in the extended release composition; c) 15-35% wt in the rapid release or immediate release composition and 85-65% wt in the extended release composition; d) 15-25% wt in the rapid release or immediate release composition and 85-75% wt in the extended release composition; e) 15-20% wt in the rapid release or immediate release composition and 85-80% wt in the extended release composition; f) 20% wt or less in the rapid release or immediate release composition and 80% wt or more in the extended release composition; g) about 18% wt in the rapid release or immediate release composition and about 82% wt in the extended release composition; or h) about 22% wt in the rapid release or immediate release composition and about 78% wt in the extended release composition.
5. The dosage form of claim 3 , wherein the dosage form exhibits an in vitro release profile selected from any one of the following for the total amount of MPH or salt thereof released from the extended release composition and the rapid release or immediate release composition:
Deionized water
Deionized water
Deionized water
Dissolution
Dissolution
Dissolution
Time
(% wt) Median
(% wt) Median
(% wt) Median
(hr)
or mean range
or mean range
or mean range
1
20-30
22-27
21-27
2
25-35
29-33
27-34
4
45-60
51-57
46-57
6
68-85
74-83
68-83
8
90-100
97-100
92-100
10
91-100
99-100
95-100.
6. The dosage form of claim 3 , wherein the total amount of MPH or salt thereof in the dosage form is about 2.5 mg, about 5 mg, about 7.5 mg, about 9 mg, about 10 mg, about 12.5 mg, about 14 mg, about 15 mg, about 17.5 mg, about 18 mg, about 20 mg, about 25 mg, about 27 mg, about 30 mg, about 35 mg, about 36 mg, about 40 mg, about 45 mg, about 50 mg, about 54 mg, about 60 mg, about 63 mg, about 70 mg, about 72 mg, about 75 mg, about 80 mg, about 81 mg, or about 90 mg.
7. A method of treating a condition that is therapeutically responsive to MPH or salt thereof, the method comprising orally administering at least one dosage form according to claim 1 .
8. The method of claim 7 , wherein the condition is selected from the group consisting of attention deficit hyperactivity disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, fatigue, bipolar disorder, lack of attention, opioid induced somnolence, major depressive disorder and obesity.
9. A method of treating a condition that is therapeutically responsive to MPH or salt thereof, the method comprising orally administering at least one dosage form according to claim 2 .
10. The method of claim 9 , wherein the condition is selected from the group consisting of attention deficit hyperactivity disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, fatigue, bipolar disorder, lack of attention, opioid induced somnolence, major depressive disorder and obesity.
11. A method of treating a condition that is therapeutically responsive to MPH or salt thereof, the method comprising orally administering at least one dosage form according to claim 3 .
12. The method of claim 11 , wherein the condition is selected from the group consisting of attention deficit hyperactivity disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, fatigue, bipolar disorder, lack of attention, opioid induced somnolence, major depressive disorder and obesity.
13. A method of treating a condition that is therapeutically responsive to MPH or salt thereof, the method comprising orally administering at least one dosage form according to claim 4 .
14. The method of claim 13 , wherein the condition is selected from the group consisting of attention deficit hyperactivity disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, fatigue, bipolar disorder, lack of attention, opioid induced somnolence, major depressive disorder and obesity.
15. A method of treating a condition that is therapeutically responsive to MPH or salt thereof, the method comprising orally administering at least one dosage form according to claim 5 .
16. The method of claim 15 , wherein the condition is selected from the group consisting of attention deficit hyperactivity disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, fatigue, bipolar disorder, lack of attention, opioid induced somnolence, major depressive disorder and obesity.
17. A method of treating a condition that is therapeutically responsive to MPH or salt thereof, the method comprising orally administering at least one dosage form according to claim 6 .
18. The method of claim 17 , wherein the condition is selected from the group consisting of attention deficit hyperactivity disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, fatigue, bipolar disorder, lack of attention, opioid induced somnolence, major depressive disorder and obesity.